text:
Increased sexuality activity has been long linked to higher testosterone levels, which would pose a higher risk of prostatic cancer. Of course, intense sexual activity also exposes the individual to sexually transmitted diseases, also a big risk factor for prostate cancer. But a long-term research at US National Cancer Institute came with a big surprise.
The Follow-up Study enrolled 29,342 males between 40 and 75 and were asked about possible risk factors for cancer and other chronic conditions. For 8 years the subjects were questioned about the frequency of ejaculation, no matter if by sexual intercourse, nocturnal emission and masturbation.
The participants reported the monthly average number of ejaculations when they were 20 to 29, 40 to 49 yeras old, and during the previous year, in a range of frequencies of 1-3, 4-7, 8-12, 13-20, or more than 21 ejaculations per month. Subjects were also asked to report if they had been diagnosed with prostate cancer in the previous two years. 1449 cases of prostate cancer were found.
Of course, the average number of ejaculations per month decreased with the age, from 15.1 at the age of 20-29, to 5.0 for males over 60.
58% of the subjects reported 3 or more ejaculations per week at 20-29, 32% at 40-49 of an age, 22% at 50-59, and 5% in older than 60.
Those with a history of high ejaculation frequency over their lifetime were physically fit but also had a richer history of a sexually transmitted disease, prostatitis and vasectomy. These men were also more likely to be not engaged in a long-term relationship (divorced or separated), consume more total calories, fish, alcohol and food supplements.
Researchers made corrections to their study in connection to the age, race, family history of prostate cancer, vasectomy, body mass at age 21, height, smoking years, type 2 diabetes, physical activity and calorie, fructose, vitamin E, zinc, meat, fish and alcohol intake.
A mean ejaculation frequency of 21 or more times monthly at 40-49, or over 13 per month during a lifetime was connected to a low risk of prostate cancer. This link was not connected to age, family history, sexual transmitted disease, smoking, or diet.
The researchers suspect that frequent ejaculations may damp into the prostatic fluid carcinogenic chemicals, like xenobiotics and others.
Frequent ejaculation could also decrease the development of intraluminal prostatic crystalloids, linked by many researchers to prostate tumors.


text:
Strategy, Development, Marketing Support, and Syndication
Real Time Data, Contextual Computing & Analytics
Technology, Digital Networks & Marketplaces
Gamification, Payments & Rewards
Development, Marketing & Partnerships
Management & Project Collaboration
Brand Development Frameworks & Partnerships
Business Development & PR
Relations & Partnerships
Innovative Products & Fulfillment
Speaking, Education & Entertainment
The best people are the ones who really understand the content and are a pain in the butt to manage. But you put up with it because they're so great at the content. And that's what makes great products. It's not process. It's content. Steve Jobs

subset: commoncrawl


text:
This little-known museum on the north side of the University College quad houses the private collection of New York City psychoanalyst Dr Lillian Malcove Ormos. Medieval ivories and a stunning 1538 panel painting of Adam and Eve by Lucas Cranach are on view, though regular exhibits are occasionally pushed aside by travelling shows.
Area Toronto
Transport Bus 94/streetcar 506/subway Queen's Park
Telephone 416 978 1838
Open Sept-June 10am-6pm Tue-Thur, Sun; 10am-9pm Fri; noon-4pm Sat. July, Aug noon-5pm Tue-Fri.
Admission free.


text:
'CSI: Miami' Star Is Expecting
by Tracy Phillips | July 27, 2010 at 10:21 AM | TV News
'CSI: Miami' star Emily Procter is pregnant, reports TV Guide.
Procter, 41, is expecting her first child with her musician husband Paul Bryan, 43.
According to TV Guide, the hot 'Miami' mama's pregnancy will not be written into her character Calleigh Duquesne's storyline.
The new season of 'CSI: Miami' returns on a new night, Sunday, October 3 at 10 p.m./EST on CBS.


text:
.The actual fungus likes dark, comfortable, humid not to mention wet spaces.That is why locker sites are infamous for experiencing the fungus.There's virtually no chance of advoiding it with growing.Despite constant cleaning of their surfaces there may be still basically no guarantee that hot weather won't keep form.

For those who have had runners foot, have you realized that your infected with the virus foot always it seems to itch much more after taking off your socks together with shoes at the conclusion of manufactured? This happens because your feet are warm and even moist inside shoes right through the day
. And it does matter?-to the aim of finding the possibility to promote damaged domestic pride and then inter-state stress. Any time Us all Squad Leader Dennis Ralston was basically shown any Davis Mug in 1972 on Bucharest, following what an English tongue commentator referred to as ?¡ãthe noisiest, angriest, just about the most absorbing and quite a few enthusiastic contest in your reputation for Davis Tumbler contest,?¡à Ralston thanked ?¡ã??the very good many people associated with Budapest?¡¥ with regard to their goodness together with speech for the remembrances north america
.

Corset style leather outfits are an added bonus as they are laced up. If your outfit is a chore to get on, it is probably going to be a chore to get off. No man wants to fiddle with fancy zippers and straps to get you out of your outfit. With corsets, you can just tug on the ties. If it is a two-piece outfit, it can easily be pushed up, down, or tugged off. If it is a one piece, all you will need to do is shimmy out of it, and you will be ready to go to the next level during your evening of passion
...until then this unique jumper is definitely count when iconic and also timeless design this valuable days or weeks. What's more you can also find a few handy reason people making use of leather-based fleece especially in the motorcyclist. Regardless that biking using a pair of wheeler car is undoubtedly pleasing it can also be dangerous, moist cloth resources ' a strong resilience ingredient that will can protect you out of the features on a road trip such as debris, pollution and additionally insects, while you're on the other side straightforward denims might be ruin simply however wash rag fails to injury conveniently
.You can cut costs by giving your stay in a day or maybe two so that you can avoid the widely used dates.You can find good deals should you fly in Wednesdays not to mention Saturday days.

Try and fly through weekdays.This is really because the weekday flights usually are not full thus the airline carriers offer marked down rates so that they can fill in your seats.It's not the circumstance with end of the week flights which have been full.The mark down tickets on the other hand disappear after they can be released
.

How are we ever going to get beyond the "us-them" mentality, the "my God is better than your God" confusion and the "God's gonna get you" understanding of the divine? Please. Let's leave nations and wars and politics and customs and rituals and social order out of religion. I know there is a Holy Spirit, or else why would a physical body be given the grace to automatically heal itself? But the Holy Spirit of my world is completely above fleeting, physical human issues
. But that's not all, development of the child various gadgets that have going getting design states, seeing that style is much more favorite. Could decide among several different types.
Expedition Grasp Form teams outfits, which often can attribute from a used car traditional 12-volt electrical socket, supplies remarkable levels of privacy and additionally tenderness. With this apparel, consumers is nice with out gaining substantial sheets of garments. This unique dress assists with dealing with lethargy whilst sealing entertainment not to mention defense, by giving including a great deal of heat
Die 4. Augenbraue
40 Jahre ELO


text:
- Employees in region:
- 429
- Sector:
- Manufacturing
- HQ location:
- Houston, TX
'10, '11, '12, '13, '14
Hilcorp, founded in 1989, is one of the largest privately-held independent oil and natural gas exploration and production companies in the United States and is the largest onshore oil producer in Louisiana. Headquartered in Houston, TX., Hilcorp has over 1,100 employees and operates properties in a number of regions that include Texas, Louisiana, Alaska, and the Northeast United States. In operating across the United States, Hilcorp continues to grow by actively acquiring and operating conventional assets while expanding its footprint into a number of new resource plays.
When you work at Hilcorp, seeing our Core Values in action every day inspires you to be a part of our ?Vision? to be the premier private energy company, in America. Our Core Values are, Ownership ? ?Work Like You Own the Company,? Urgency ? ?Act Today, Not Tomorrow?, Alignment ? ?When Hilcorp Wins, We All Win?, Innovation? ?Get Better Every Day?, and Integrity ? ?Do the Right Thing?.
"Great people, great place, great pay."
"Hilcorp is a fun place to work and is challenging."
"I feel like I am contributing to something meaningful."
"It is mentally stimulating and financially very satisfying."
"We are successful as a company and rewarded well."
"The freedom of the people on the front line to have real impact."


text:
The influence of resident gut microbes on xenobiotic metabolism has been investigated at different levels throughout the past five decades. However, with the advance in sequencing and pyrotagging technologies, addressing the influence of microbes on xenobiotics had to evolve from assessing direct metabolic effects on toxins and botanicals by conventional culture-based techniques to elucidating the role of community composition on drugs metabolic profiles through DNA sequence-based phylogeny and metagenomics. Following the completion of the Human Genome Project, the rapid, substantial growth of the Human Microbiome Project (HMP) opens new horizons for studying how microbiome compositional and functional variations affect drug action, fate, and toxicity (pharmacomicrobiomics), notably in the human gut. The HMP continues to characterize the microbial communities associated with the human gut, determine whether there is a common gut microbiome profile shared among healthy humans, and investigate the effect of its alterations on health. Here, we offer a glimpse into the known effects of the gut microbiota on xenobiotic metabolism, with emphasis on cases where microbiome variations lead to different therapeutic outcomes. We discuss a few examples representing how the microbiome interacts with human metabolic enzymes in the liver and intestine. In addition, we attempt to envisage a roadmap for the future implications of the HMP on therapeutics and personalized medicine.
Keywords:Human microbiome project; Xenobitoics; Liver enzymes; Metagenome; Microbiota; Metabolomics; Metabonomics; Pharmacokinetics; Pharmacodynamics; Pharmacomicrobiomics
The gut microbiota is the most predominant and most diverse microbial community residing in the human body [1]. It comprises hundreds of microbial species, together constituting about 10 times the number of body cells [2,3], and contributes substantially to human metabolic processes to the extent that up to 36 % of small molecules in human blood are contributed by the gut microbiome [4]. The gut microbiota's impact on drug response and metabolism has been explored since the mid 20th century (reviewed in [5]); however, past studies have mostly focused on assessing the metabolic activity of gut microbial communities on antibiotics and botanicals [6-9]. Meanwhile, the influence of the host genetic makeup on drug response occupied the center stage of personalized medicine research, specifically in the clinical domain, leading to the rise of pharmacogenomic approaches to personalized therapy, while a pivotal player in xenobiotic metabolism, the microbiota, was mostly being overlooked [10,11].
The various metabolic capabilities of the gut microbiota fueled the study of its effects on drug metabolism [11,12]. Several approaches were adopted, including comparisons between metabolic patterns of conventional and germfree mice, biochemical assays of microbial metabolic activities in cultures, and mutagenicity tests [5,6,13]. Population-based approaches, such as investigating the correlation between compositional variations in gut microbiota and response to a particular drug, e.g., digoxin, were followed as well [9].
The evolution of microbial genomics from culture-based (i.e., sequencing genomes of bacterial species after isolating their colonies) to culture-independent strategies (metagenomics—or shotgun sequencing of microbial and viral communities [14,15]) has allowed the identification of the molecular signature of the gut microbiome associated with a certain disease or with altered drug response [16]. To describe this new expansion of pharmacogenomics, we suggested the term pharmacomicrobiomics to denote the effect of microbiome variations on drug disposition and response [17,18]; here, we apply this concept explicitly to the human gut microbiome, the best-studied microbiome for its effect on xenobiotics.
In a broad sense, the term gut pharmacomicrobiomics encompasses the effect of the gut microbiome variations on pharmacokinetic and pharmacodynamic processes [17,19] (See Section "Term disambiguation"). However, to date, the better-documented effects of the human gut metagenome on drugs are those related to metabolism (i.e., effects on pharmacokinetic), either through: (i) the secretion of enzymes that modify the chemical structure of drug molecules, (ii) the secretion of metabolic products that interfere with drug metabolism, (iii) the modification of the levels and activities of liver and intestinal enzymes, or (iv) the modulation of expression of human metabolic genes [16] (Figure 1). Taking into consideration the enormous number of gut-associated microbes, and the extremely large number of diverse genes they encode and pathways they express, understanding the effect of the gut microbiota on human response to drugs is an indispensable step towards providing a comprehensively tailored/personalized therapy that would be more efficient, cost-effective, and with lower adverse drug events [17,20].
Figure 1. Different ways of interactions between the gut microbiome and drugs, sometimes involving dietary compounds or intestinal and liver enzymes. Liver and intestine cartoons were taken from the publicly available clipart of the University of Wisconsin, Madison. URL: http://www.biochem.wisc.edu/medialab/clipart.aspx. webcite.
In this review, we aim at providing an overview of the influence of gut microbiota on drugs, spanning the documented metabolic effects of the microbiota and the different approaches used for their investigation. In addition, we provide an outlook for the future of pharmacomicrobiomics in the context of the Human Microbiome Project (HMP) and for the application of metagenomic approaches as an integral part of pharmacotherapy and personalized medicine.
Term disambiguation
•Microbiome and microbiomics: To the best of our knowledge, the term 'microbiome' was first suggested in 2000 by the Nobel Laureate, Joshua Lederberg, to describe the sum of microbial genomes associated with the human body, which he described as a part of "the human extended genome" (URL: http://www.project-syndicate.org/commentary/microbiology-s-world-wide-web webcite). Soon after, it was used in the same meaning in literature [21,22]. Currently, however, microbiome is being used to denote two different concepts: (i) the collective microbial genome of a community (i.e., microbial metagenome) or (ii) the sum of all microscopic life forms, viz. microbes, within an environment (i.e., micro.biome). Microbiome was initially confined to host-associated metagenomes, but is now being used interchangeably with microbial metagenome (e.g., the Earth Microbiome Project http://www.earthmicrobiome.org/ webcite[23]). The less frequently used term, 'microbiomics', describes the study of functional aspects related to the microbiome, including the integration of high-throughput genome-wide data [24].
•Pharmacogenomics and pharmacomicrobiomics: Pharmacogenomics [25] is a well-established term that describes the effect of human genome variations on drug disposition and action. The term can certainly be applied not just to the human nuclear and mitochondrial genomes, but also to the human extended genome or the genome of the human supraorganism [18]; yet, to specify the impact of the human-associated microbiome on drugs, we have coined the term pharmacomicrobiomics [17,18], which we consider as a natural expansion of pharmacogenomics, which is likely to spread when more HMP data accrue.
•Metabolomics and metabonomics: Those two verbally similar terms have been sometimes used interchangeably to describe the high-throughput study of all genome-encoded metabolites produced by a particular organism or a community; however, Nicholson and coworkers carefully denote the difference between the two terms as they use metabolomics to describe the study of genetically controlled metabolites and fluxes produced by one type of cells or tissues, whereas they define metabonomics as the measurement of metabolites produced by a collection of cells/genomes within a multicellular organism or an ecosystem [26] (the latter once described as the 'meta-metabolome' [27]).
Role of gut microbiota in xenobiotic metabolism
The influence of the gut microbiota on the metabolism of xenobiotics has been regarded extensively as a response-modifying process, and several mechanisms have been proposed and demonstrated [11]. Gut-associated microbes can alter drug metabolism directly by producing enzymes that degrade or activate the drug molecules, or by competing with drug molecules over the metabolizing enzymes [17,20]. In addition, the gut microbiota may exert its influence by modulating the activity or altering the levels of the host's drug-metabolizing enzymes or by producing enzyme-inducing metabolites that are originally derived from diet [28,29] (Figure 1). Accordingly, the microbiome's response-modifying effect has been widely appreciated in nutrition and toxicology, and the role of gut microbiota in metabolism has initially been investigated in terms of the metabolism of compounds of dietary and botanical origin (Table 1).
Table 1. Role of gut microbiota in the metabolism of dietary compounds and phytochemicals
Additionally, the absence of conventional gut microbiota in germfree mice has been correlated with perturbations in levels of liver and intestinal metabolic enzymes in comparison to their corresponding levels in mice with conventional gut ecosystem [29], and conventional gut microbiotas in human and mice were shown to be associated with a modest elevation in the levels of drug-metabolizing enzymes, such as sulfotransferase1 B1 (SULT1B1) and with reduced levels of other enzymes, such as SULT1C1, NAT1 and NAT2 [28] (Table 2).
Impact of microbiome variations on drug response and toxicity
Most studies on drug-microbe interactions did not take in consideration the microbiome profile/composition of an individual or a population; however, these variations are the basis of pharmacomicrobiomics, and their study has become possible now that the HMP has been established [3,41], and HMP data have already been made available [1,42].
Several studies associated a particular 16S rRNA microbial signature with specific biomarker metabolites and clinical outcomes. This association has been extended to encompass several conventional drugs such as digoxin and acetaminophen [9,43]. Profiling the signatures of the microbial communities in relation to their metabolic effect on drugs among patients is likely to introduce clinical markers that will dictate treatment regimens tailored in accordance with each patient's resident microbiota [43]. Such regimens, in turn, will modify the current treatment strategies that are based on conventional pathologic and pharmacokinetic parameters to take into account the interindividual perturbations in the gut microbiota and the gut ecosystem. These measures are especially true with the evidence of the sym-xenobiotic metabolism that involves both the host and the associated microbiota to biotransform drugs, including first-line therapies [9,44] (Table 3). As a consequence, microbiome-labile medications may be limited, or their dose readjusted, for certain populations or individuals harboring particular gut microbial community profiles. Several drugs that possess structural similarity to microbial products and are thereby potential candidates of microbial metabolism are yet to be studied.
Table 3. Role of gut microbiota in the metabolism of conventional first line therapies and over-the-counter (OTC) drugs
A systems biology view of the host-microbiota metabolome and co-metabolome
Previously reported drug-microbe and drug-microbiome interactions have mostly been described as phenotypic observations of drugs being modified by a microbial species, an entire microbial community, or an even more intricate system consisting of a microbial and a human component. However, in many cases the process, biochemical pathway, or specific reaction remains unknown, which renders the analysis of those interactions by reductionist approaches difficult. Instead, exploring the causality of those interactions might require systems approaches such as the metagenomic analysis of the microbial community followed by the identification of differentially abundant or differentially expressed candidate genes or genomic subsystems [52] involved in those interactions. Yet, metagenomic surveys that determine microbial community profiles, gene presence/absence and abundance, or functional classification of sequence fragments are not sufficient to tell a coherent story about the observed phenotypes since a gene's presence does not imply its expression or functionality. Consequently, extracting knowledge from those microbiome explorations and translating them into an ultimately tailored therapy requires modeling the human microbiome, variome, and interactions between them via integrating multiple layers of information, including transcriptomic, proteomic, and metabolomic data. Such integration is not always achievable in a system with this complexity. For instance, a statistically sound correlation between mRNA and protein expression levels in mid-log phase Saccharomyces cerevisiae cells has been hindered by technical limitations [53]. If this was the case with a unicellular organism or with relatively uniform cell lines [54], then further levels of complexity are to be expected in the gut microbiome ecosystem, where communities of unicellular organisms coexist in balance with the human multicellular tissues. Systems biology approaches for such complex communities are inevitable but are still in early development [55,56].
From a holistic perspective, tailoring a pharmacotherapy that accommodates intraindividual and interindividual variations would take into account the variations in the host's genetic makeup, its associated-microbiome, and metabolomic interactions between the host and its associated microbiota (i.e., co-metabolome). With the recognition of the considerable role of the human microbiome and its variations together with the formerly well-recognized role of the human variome in predicting response to pharmacotherapy, there is a growing demand in both clinical and research domains for proper computational models that are able to comprehensively consider all such aspects of variability [26,53,54]. The best-recognized process in altered drug response, controlled by both human genome and microbiome, is the presystemic metabolism or first-pass effect (reviewed in [57]). Since the metabolism of xenobiotics in humas is performed by host and microbial enzymes, the metabolic process is recognized as combinatorial or "sym-xenobiotic" as recently described [10]. Furthermore, a continuous metabolic interaction, termed metabolome-metabolome interaction, exists between the host and its associated microbiota [10]. Modeling the human/microbiome variations and metabolome-metabolome interactions will provide insights into the metabolism of xenobiotics and thereby allow for accurate predictions for drug response [26].
Nicholson and colleagues [26] attempted to visualize the role of both the host and its associated microbiota in xenobiotic metabolism in the gut by proposing an interesting model, assuming six different cell types in both host and microbiota, every type of which has its own transcriptome and metabolome depending on its role. There is a mutual metabolic exchange between the host and microbiota, and the extracellular compartment contains metabolites generated by both of them. Those metabolites are the result of drug and food metabolism, and might lead to metabolic alterations in both the host and its associated microbiota. This probabilistic model of metabolism was introduced in an attempt to tackle the potential interaction between the different host- and microbiome-related factors that would eventually display a certain outcome for metabolism. The model likens the complex process of drug metabolism to a Japanese Pachinko (pinball machine), where pins represent enzymes and transporters involved in metabolism, holes indicate outlets for metabolites, and pathways are represented by the sequence of pins. According to this model, the final outcome is the increment of the probabilities of collisions between pins and balls [26].
Web resources for exploring gut pharmacomicrobiomics
•Human variome resources:
•HVP (Human Variome Project): http://www.humanvariomeproject.org webcite[58]
•HapMap: http://hapmap.ncbi.nlm.nih.gov webcite[59]
•Human microbiome resources:
•MetaHIT (Metagenomics of the Human Intestinal Tract): http://www.metahit.eu webcite[42]
•HMP: http://hmpdacc.org webcite[41]
•Tools or databases for browsing the human microbiome:
•IMG/HMP: http://www.hmpdacc-resources.org/cgi-bin/imgm_hmp/main.cgi webcite[41]
•myMGDB: http://edwards.sdsu.edu/cgi-bin/mymgdb/show.cgi webcite
•MG-RAST: http://metagenomics.anl.gov webcite[60]
•The SEED Servers: http://www.theseed.org/servers webcite[61]
•Pharmacogenomics/pharmacomicrobiomics databases:
•PharmGKB (Pharmacogenomics Knowledge Base): http://www.pharmgkb.org webcite[62]
•PacDB (Pharmacogenetics and Cell Database): http://www.pacdb.org webcite[63]
•CTDB (Comparative Toxigenomics Database): http://ctdbase.org webcite[64]
•The PharmacoMicrobiomics Portal: http://www.pharmacomicrobiomics.org webcite[65]
•Enzymes/pathways databases:
•KEGG (Kyoto Encyclopedia of Genes and Genomes): http://www.genome.jp/kegg/ webcite[66]
•Model SEED: http://seed-viewer.theseed.org/seedviewer.cgi?page=ModelView webcite[67]
•BRENDA (BRaunschweig ENzyme Database): http://www.brenda-enzymes.org webcite[68]
Future anticipations
The current advances in the Human Variome Project [69,70] and the HMP [3,41], together with a battery of publicly available web resources (See Section "Web resources for exploring gut pharmacomicrobiomics") offer a starting point for those interested in drug-microbiome interactions to address several intriguing questions. However, the examples reported previously (e.g., those in Tables 1, 2 and 3) are just the tip of an iceberg of yet-to-be-discovered interactions between the host variome, associated microbiome, their combined metabolome, and chemicals ingested by humans. Ultimately, the study of those interactions in spite of their complexity is driven by the need for devising personalized therapeutic regimens aiming at optimizing drug bioavailability to obtain maximal efficiency and minimal toxicity. Below, we suggest a roadmap of four steps for the development of the nascent field of gut pharmacomicrobiomics and its translation into personalized medicine (Figure 2).
Figure 2. A roadmap for the development of the nascent field of gut pharmacomicrobiomics and its translation into the clinical domain.
Capturing current knowledge
The first step is to capture and organize the currently available information on drug-microbiome complex interactions by building databases similar to those built for pharmacogenetics, pharmacogenomics, and drug-drug interactions. Concomitant with building databases is developing tools and resources to support discovery by mining those databases and connecting them to microbial genomic databases (e.g., SEED [61], GOLD [71]) metagenomic/microbiome databases, (e.g., MG-RAST [60], myMGDB, HMP [41], METAHIT [42]), and metabolic pathway databases (e.g., KEGG [66], modelSEED [67], BRENDA [68]).
Developing and performing high-throughput screens for novel drug-microbiome interactions
In parallel with capturing existing knowledge, there is continuous need for digging deeper into the unknown drug-microbiome interaction space. Addressing this need can be achieved via studies involving high-throughput screens of drugs against human microbiota from different individuals looking at the overall action of these microbiotas on representatives of different drug classes, or, reciprocally, via screening individual resident gut microbes against large libraries of drugs or other chemicals.
Developing software and building models for drug response simulation
The accumulated data in literature pointing out to the response variation mediated by mammalian host variome and microbiome calls for the construction of modeling software that considers all such parameters to provide rational hypotheses or accurate predictions for research [26,55,72]. Developing such modeling software and using it in building models requires encoding data compiled from the literature regarding the host variome, microbiome and co-metabolome, and incorporating these encoded data into a model capable of retrieving an informative index describing the predicted outcome. For instance, Hlavaty and colleagues [73] used a similar approach to construct a predictive model of an apoptotic pharmacogenetic index for infliximab in treatment of Crohn disease. Following data mining, they used SAS® enterprise miner software to analyze all the genetic variants involved with the apoptotic response of infliximab, they managed to develop a new pharmacogenetic index ranging from 0 which denotes diminished response to 3, indicating a powerful response [73].
Data integration and translation into the clinical domain
The availability of web resources, the generation of more data, and the construction of rigorous models for drug-microbiome interactions will offer a great opportunity to translate this knowledge into diagnostic and clinical measures. In the future, routing clinical practices should include integrating microbiome data and processing them to produce valid assumptions of clinical outcome, based on which the type, dose, and regimen of treatment will be planned for each patient. Accordingly, each case will have its own panel of personalized therapy. For instance, patients harboring gut microbiota known to be associated with elevated levels of metabolic enzymes will be scheduled for higher doses; patients with higher susceptibility to acetaminophen toxicity might either be given a lower dose or an alternative nonsteroidal anti-inflammatory medicine; and patients with a microbiota with higher ability to metabolize digoxin will be scheduled to receive lower dose.
Throughout the past five decades, the study of the effect of gut microbiota went through several phases uncovering its ample significance in drug response. With the continuous growth of the HMP and its expansion to cover diverse human populations, it is anticipated that the primary data concerning the common gut microbiome profile and its diversity among humans will be revealed, enabling to pursue further studies on its effect on drug response among populations. However, several steps are yet to be taken in anticipation of the floods of HMP data, including the construction of databases, software, and models that would provide credible predictions of differential clinical outcome and fuel further hypothesis-driven studies whose findings might be integrated into clinical settings.
Competing interests
The authors declare that they have no personal or financial competing interests.
Authors' contributions
RS reviewed literature, collected data, outlined and drafted the manuscript, and participated in writing the final version. MRR collected data and abstracts, and participated in writing the final version. RKA conceived the article, reviewed literature, and wrote the article in its final format. All authors read and approved the final manuscript.
Authors' information
Rama Saad is currently a visiting scholar at Vanderbilt University Medical Center, Nashville, TN, USA.
We thank Ms. Radwa Raed Sharaf for critical reading of the draft and help with proofreading the final version.
Human Microbiome Project Consortium: Structure, function and diversity of the healthy human microbiome.
Nature 2012, 486:207-214. PubMed Abstract | Publisher Full Text
Savage DC: Microbial ecology of the gastrointestinal tract.
Annu Rev Microbiol 1977, 31:107-133. PubMed Abstract | Publisher Full Text
Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, Bonazzi V, McEwen JE, Wetterstrand KA, Deal C, et al.: The NIH Human Microbiome Project.
Genome Res 2009, 19:2317-2323. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Hood L: Tackling the microbiome.
Science 2012, 336:1209. PubMed Abstract | Publisher Full Text
Goldman P, Peppercorn MA, Goldin BR: Metabolism of drugs by microorganisms in the intestine.
Am J Clin Nutr 1974, 27:1348-1355. PubMed Abstract | Publisher Full Text
Holt R: The bacterial degradation of chloramphenicol.
Lancet 1967, 1:1259-1260. PubMed Abstract
Spatz M, Smith DW, McDaniel EG, Laqueur GL: Role of intestinal microorganisms in determining cycasin toxicity.
Proc Soc Exp Biol Med 1967, 124:691-697. PubMed Abstract
Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR: Inactivation of digoxin by the gut flora: reversal by antibiotic therapy.
N Engl J Med 1981, 305:789-794. PubMed Abstract | Publisher Full Text
Mathan VI, Wiederman J, Dobkin JF, Lindenbaum J: Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora.
Gut 1989, 30:971-977. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Nicholson JK, Holmes E, Wilson ID: Gut microorganisms, mammalian metabolism and personalized health care.
Nat Rev Microbiol 2005, 3:431-438. PubMed Abstract | Publisher Full Text
Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW: The gastrointestinal microbiota as a site for the biotransformation of drugs.
Int J Pharm 2008, 363:1-25. PubMed Abstract | Publisher Full Text
Johnson CH, Patterson AD, Idle JR, Gonzalez FJ: Xenobiotic metabolomics: major impact on the metabolome.
Annu Rev Pharmacol Toxicol 2012, 52:37-56. PubMed Abstract | Publisher Full Text
Koch RL, Chrystal EJ, Beaulieu BB Jr, Goldman P: Acetamide–a metabolite of metronidazole formed by the intestinal flora.
Biochem Pharmacol 1979, 28:3611-3615. PubMed Abstract | Publisher Full Text
Riesenfeld CS, Schloss PD, Handelsman J: Metagenomics: genomic analysis of microbial communities.
Annu Rev Genet 2004, 38:525-552. PubMed Abstract | Publisher Full Text
Edwards RA, Rohwer F: Viral metagenomics.
Nat Rev Microbiol 2005, 3:504-510. PubMed Abstract | Publisher Full Text
Haiser HJ, Turnbaugh PJ: Developing a metagenomic view of xenobiotic metabolism.
Pharmacol Res 2012. Publisher Full Text
Rizkallah MR, Saad R, Aziz RK: The Human Microbiome Project, personalized medicine and the birth of pharmacomicrobiomics.
Aziz RK: Rethinking pharmacogenomics in an ecosystem: drug-microbiome interactions, pharmacomicrobiomics, and personalized medicine for the human supraorganism.
Aziz RK, Saad R, Rizkallah MR: PharmacoMicrobiomics or how bugs modulate drugs: an educational initiative to explore the effects of human microbiome on drugs.
Wilson ID: Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring.
Proc Natl Acad Sci USA 2009, 106:14187-14188. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Relman DA: New technologies, human-microbe interactions, and the search for previously unrecognized pathogens.
J Infect Dis 2002, 186(Suppl 2):S254-S258. PubMed Abstract | Publisher Full Text
Shanahan F: The host-microbe interface within the gut.
Best Pract Res Clin Gastroenterol 2002, 16:915-931. PubMed Abstract | Publisher Full Text
Gilbert JA, Meyer F, Antonopoulos D, Balaji P, Brown CT, Desai N, Eisen JA, Evers D, Field D, Feng W, et al.: Meeting report: the terabase metagenomics workshop and the vision of an Earth microbiome project.
Stand Genomic Sci 2010, 3:243-248. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Egert M, de Graaf AA, Smidt H, de Vos WM, Venema K: Beyond diversity: functional microbiomics of the human colon.
Trends Microbiol 2006, 14:86-91. PubMed Abstract | Publisher Full Text
Persidis A: The business of pharmacogenomics.
Nat Biotechnol 1998, 16:209-210. PubMed Abstract | Publisher Full Text
Nicholson JK, Wilson ID: Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism.
Nat Rev Drug Discov 2003, 2:668-676. PubMed Abstract | Publisher Full Text
Ibrahim M, Anishetty S: A meta-metabolome network of carbohydrate metabolism: Interactions between gut microbiota and host.
Biochem Biophys Res Commun 2012, 428(2):278-284. PubMed Abstract | Publisher Full Text
Meinl W, Sczesny S, Brigelius-Flohe R, Blaut M, Glatt H: Impact of gut microbiota on intestinal and hepatic levels of phase 2 xenobiotic-metabolizing enzymes in the rat.
Drug Metab Dispos 2009, 37:1179-1186. PubMed Abstract | Publisher Full Text
Overvik E, Lindeskog P, Midtvedt T, Gustafsson JA: Mutagen excretion and cytochrome P-450-dependent activity in germfree and conventional rats fed a diet containing fried meat.
Food Chem Toxicol 1990, 28:253-261. PubMed Abstract | Publisher Full Text
Sugimura T, Nagao M, Wakabayashi K: Carcinogenicity of food mutagens.
Environ Health Perspect 1996, 104(Suppl 3):429-433. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Rowland IR: Interactions of the gut microflora and the host in toxicology.
Toxicol Pathol 1988, 16:147-153. PubMed Abstract | Publisher Full Text
Lhoste EF, Ouriet V, Bruel S, Flinois JP, Brezillon C, Magdalou J, Cheze C, Nugon-Baudon L: The human colonic microflora influences the alterations of xenobiotic-metabolizing enzymes by catechins in male F344 rats.
Food Chem Toxicol 2003, 41:695-702. PubMed Abstract | Publisher Full Text
Axelson M, Sjovall J: Formation of catechol estrogens by intestinal bacterial demethylation of 2-methoxyestrone.
Biochim Biophys Acta 1983, 751:162-165. PubMed Abstract | Publisher Full Text
Gonthier MP, Verny MA, Besson C, Remesy C, Scalbert A: Chlorogenic acid bioavailability largely depends on its metabolism by the gut microflora in rats.
J Nutr 2003, 133:1853-1859. PubMed Abstract | Publisher Full Text
Gavaghan CL, Nicholson JK, Connor SC, Wilson ID, Wright B, Holmes E: Directly coupled high-performance liquid chromatography and nuclear magnetic resonance spectroscopic with chemometric studies on metabolic variation in Sprague–Dawley rats.
Anal Biochem 2001, 291:245-252. PubMed Abstract | Publisher Full Text
Bowey E, Adlercreutz H, Rowland I: Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats.
Food Chem Toxicol 2003, 41:631-636. PubMed Abstract | Publisher Full Text
Delgado S, Ruas-Madiedo P, Suarez A, Mayo B: Interindividual differences in microbial counts and biochemical-associated variables in the feces of healthy Spanish adults.
Dig Dis Sci 2006, 51:737-743. PubMed Abstract | Publisher Full Text
Akao T, Kawabata K, Yanagisawa E, Ishihara K, Mizuhara Y, Wakui Y, Sakashita Y, Kobashi K: Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form.
J Pharm Pharmacol 2000, 52:1563-1568. PubMed Abstract
Selma MV, Espin JC, Tomas-Barberan FA: Interaction between phenolics and gut microbiota: role in human health.
J Agric Food Chem 2009, 57:6485-6501. PubMed Abstract | Publisher Full Text
Bolton EE, Wang Y, Thiessen PA, Bryant SH: PubChem: integrated platform of small molecules and biological activities.
Proctor LM: The Human Microbiome Project in 2011 and beyond.
Cell Host Microbe 2011, 10:287-291. PubMed Abstract | Publisher Full Text
Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, et al.: A human gut microbial gene catalogue established by metagenomic sequencing.
Nature 2010, 464:59-65. PubMed Abstract | Publisher Full Text
Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK: Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism.
Proc Natl Acad Sci USA 2009, 106:14728-14733. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Vermes A, Kuijper EJ, Guchelaar HJ, Dankert J: An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora.
Chemotherapy 2003, 49:17-23. PubMed Abstract | Publisher Full Text
Grundmann O: The gut microbiome and pre-systemic metabolism: current state and evolving research.
Steffens LS, Nicholson S, Paul LV, Nord CE, Patrick S, Abratt VR: Bacteroides fragilis RecA protein overexpression causes resistance to metronidazole.
Res Microbiol 2010, 161:346-354. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Strong HA, Renwick AG, George CF, Liu YF, Hill MJ: The reduction of sulphinpyrazone and sulindac by intestinal bacteria.
Xenobiotica 1987, 17:685-696. PubMed Abstract | Publisher Full Text
Strong HA, Warner NJ, Renwick AG, George CF: Sulindac metabolism: the importance of an intact colon.
Clin Pharmacol Ther 1985, 38:387-393. PubMed Abstract | Publisher Full Text
Ashida N, Ijichi K, Watanabe Y, Machida H: Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats.
Biochem Pharmacol 1993, 46:2201-2207. PubMed Abstract | Publisher Full Text
Nakayama H, Kinouchi T, Kataoka K, Akimoto S, Matsuda Y, Ohnishi Y: Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil.
Pharmacogenetics 1997, 7:35-43. PubMed Abstract | Publisher Full Text
Kitamura S, Sugihara K, Kuwasako M, Tatsumi K: The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide.
J Pharm Pharmacol 1997, 49:253-256. PubMed Abstract
Overbeek R, Begley T, Butler RM, Choudhuri JV, Chuang HY, Cohoon M, de Crecy-Lagard V, Diaz N, Disz T, Edwards R, et al.: The subsystems approach to genome annotation and its use in the project to annotate 1000 genomes.
Nucleic Acids Res 2005, 33:5691-5702. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Gygi SP, Rochon Y, Franza BR, Aebersold R: Correlation between protein and mRNA abundance in yeast.
Mol Cell Biol 1999, 19:1720-1730. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Gry M, Rimini R, Stromberg S, Asplund A, Ponten F, Uhlen M, Nilsson P: Correlations between RNA and protein expression profiles in 23 human cell lines.
BMC Genomics 2009, 10:365. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text
Zengler K, Palsson BO: A road map for the development of community systems (CoSy) biology.
Nat Rev Microbiol 2012, 10:366-372. PubMed Abstract | Publisher Full Text
Thiele I, Heinken A, Fleming RM: A systems biology approach to studying the role of microbes in human health.
Doherty MM, Pang KS: First-pass effect: significance of the intestine for absorption and metabolism.
Drug Chem Toxicol 1997, 20:329-344. PubMed Abstract | Publisher Full Text
Howard HJ, Horaitis O, Cotton RG, Vihinen M, Dalgleish R, Robinson P, Brookes AJ, Axton M, Hoffmann R, Tuffery-Giraud S: The Human Variome Project (HVP) 2009 Forum "Towards Establishing Standards".
Hum Mutat 2010, 31:366-367. PubMed Abstract | Publisher Full Text
International HapMap Consortium: The International HapMap Project.
Nature 2003, 426:789-796. PubMed Abstract | Publisher Full Text
Meyer F, Paarmann D, D'Souza M, Olson R, Glass EM, Kubal M, Paczian T, Rodriguez A, Stevens R, Wilke A, et al.: The metagenomics RAST server - a public resource for the automatic phylogenetic and functional analysis of metagenomes.
BMC Bioinforma 2008, 9:386. BioMed Central Full Text
Aziz RK, Devoid S, Disz T, Edwards RA, Henry CS, Olsen GJ, Olson R, Overbeek R, Parrello B, Pusch GD, et al.: SEED Servers: high-performance access to the SEED genomes, annotations, and metabolic models.
PLoS One 2012, 7:e48053. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Owen RP, Altman RB, Klein TE: PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics.
Hum Mutat 2008, 29:456-460. PubMed Abstract | Publisher Full Text
Gamazon ER, Duan S, Zhang W, Huang RS, Kistner EO, Dolan ME, Cox NJ: PACdb: a database for cell-based pharmacogenomics.
Pharmacogenet Genomics 2010, 20:269-273. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Davis AP, Murphy CG, Rosenstein MC, Wiegers TC, Mattingly CJ: The Comparative Toxicogenomics Database facilitates identification and understanding of chemical-gene-disease associations: arsenic as a case study.
BMC Med Genomics 2008, 1:48. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text
Rizkallah MR SG-E, Saad R, Aziz RK: The pharmacomicrobiomics portal: a database for drug-microbiome interactions.
Curr Pharmacogenomics Person Med 2012, 10:195-203. Publisher Full Text
Kanehisa M, Goto S: KEGG: Kyoto encyclopedia of genes and genomes.
Nucleic Acids Res 2000, 28:27-30. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Henry CS, DeJongh M, Best AA, Frybarger PM, Linsay B, Stevens RL: High-throughput generation, optimization and analysis of genome-scale metabolic models.
Nat Biotechnol 2010, 28:977-982. PubMed Abstract | Publisher Full Text
Scheer M, Grote A, Chang A, Schomburg I, Munaretto C, Rother M, Sohngen C, Stelzer M, Thiele J, Schomburg D: BRENDA, the enzyme information system in 2011.
Nucleic Acids Res 2011, 39:D670-D676. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Ring HZ, Kwok PY, Cotton RG: Human Variome Project: an international collaboration to catalogue human genetic variation.
Pharmacogenomics 2006, 7:969-972. PubMed Abstract | Publisher Full Text
Ozdemir V, Rosenblatt DS, Warnich L, Srivastava S, Tadmouri GO, Aziz RK, Reddy PJ, Manamperi A, Dove ES, Joly Y, et al.: Towards an ecology of collective innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA).
Curr Pharmacogenomics Person Med 2011, 9:243-251. PubMed Abstract | PubMed Central Full Text
Pagani I, Liolios K, Jansson J, Chen IM, Smirnova T, Nosrat B, Markowitz VM, Kyrpides NC: The Genomes OnLine Database (GOLD) v.4: status of genomic and metagenomic projects and their associated metadata.
Nucleic Acids Res 2012, 40:571-579. Publisher Full Text
Heinken A, Sahoo S, Fleming RM, Thiele I: Systems-level characterization of a host-microbe metabolic symbiosis in the mammalian gut.
Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S: Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.
Inflamm Bowel Dis 2007, 13:372-379. PubMed Abstract | Publisher Full Text


text:
An Accounting of the fire:
I saw reflection of police lights and there was a terrible pounding on the door. A policeman looked at me and said, what at this point in my life are the worst five words I�ve ever heard together � �Mam, your barn�s on fire.� I felt as though I had just stepped into a nightmare. He tried to stop me but I ran, and as I slipped and slid my way down my driveway I saw the sky lit up out back and smelled the smoke. About twenty feet from the barn the heat stopped me. It was like the door on a thousand degree oven was just opened. The fire was absolute and ominous. I kept reaching for the door handle on the slider but my hand betrayed me and pulled back from the fire, it was like some horrible dream.
Where my loft door should have been was a gigantic ball of fire. It looked like the sun was trying to push its way through my loft door. And the lower doors, oh my God. There were no tongues of licking flame there either; you know what I mean, like you see in a fireplace? All around the top and side of the lower sliding door were what looked like sheets of fire; they were blowing through the tiny cracks of the door�s edges and they extended out about three feet. The sound was terrible, such a loud unholy roaring, and the black smoke was billowing from everywhere above. But the front exterior walls of the barn looked just the same as they did on a normal day. It was eerie and surreal. All I could think was� �My horses!� �Someone set my horses on fire!�
Busting down the gates and running to the back, I kept falling. I had on house slippers and the ice melting from the heat was so slick and I could hear the policeman yelling, �Don�t go back there!� If he could have stopped me without killing me or knocking me unconscious, I think my soul would have died because though I knew nothing could be alive in that awful inferno I still hoped against all reasoning that by some miracle the fire was only burning along the inside walls at the front.
Oh my God! The back door was so tightly shut and the sheets of fire were still somehow managing to billow out around the edges with such force, like some terrible rocket was trying to lift off from inside. I kept trying to reach for the door but I kept falling. I ran back to the house screaming for Phil. I knew no creature could live in that gigantic furnace that was once my barn but like a little child, I expected him to fix it. I don�t know how, but he pulled open the swinging door next to the slider on the front and the smoke just billowed out like some evil black cloud. We were both incredulous at the atrocity before us as we watched Hades rise from inside my barn. We were both incredulous at the atrocity before us as we watched Hades rise from inside my barn.
There are worse things that could happen and I�m grateful to God that they didn�t but it�s so impossible to dismiss this incident as insignificant as compared to what�s good about life. Oh, my God! Why did this have to happen? I would trade my life to spare my horses of the terror and pain that they endured. A total of eleven animals died including my three beautiful wild horses. I�m certain that it was arson but nobody else really cares. The news hit front page of two local Indiana papers ( NWI Times and Gary Post Tribune) on Dec. 30, 2010 but now it�s old news for everyone but me and Phil.
Someone out there must know who committed this horrible act and I hope that they will have the courage and decency to turn in the perpetrator(s). They could do so anonymously, they should at least notify me.


text:
School hopes to get students on the same page - a web page
By Brent Meacham
Summer is over. School's back in session. Students are arming themselves with the traditional implements of academic survival: textbooks, pens, notebooks, backpacks, headphones and the latest MP3 players.
This year's incoming students, however, will have one new tool that no Huntsman student has ever had before and this gizmo won't fit in a backpack. The Jon M. Huntsman School of Business has launched a new student-focused website.
Shara Gibbons, webmaster for the Huntsman School of Business, said the new site is aimed at meeting the student's need for quick, accurate information about college life.
"The purpose of the new website is to offer an online environment targeted at the needs of our Huntsman students," Ms. Gibbons said. "The new page will include links to information about clubs, events, classes, programs and activities."
The site is designed to be easy to navigate and includes eye-catching graphics and relevant content, Ms. Gibbons said. One unique feature incorporated into the site is links on the main page to Aggiemail and Blackboard, two key online services for all USU students.
Ms. Gibbons hopes the new site will become a place students will visit often.
"The hope is that students will want to come back to this page frequently to get the latest information about what is happening at the Huntsman School and will make the new student website their home page," she said.
Ms. Gibbons predicts this will become a pivotal connecting point between the Huntsman School and its students.
"We want it to be such a valuable and cool experience that this becomes the student's chosen homepage – and not because we said so, but because it provides relevant information that they'll need on a regular basis," Ms. Gibbons said.
Sterling Morris, a Huntsman School intern who specializes in photography and film, has helped the school with its multimedia offerings and has transformed its Facebook page.
"Our goal is to disseminate relevant information about the Huntsman School in multiple formats that satisfy all the needs of our diverse student body," Mr. Morris said.
Since 2009, the Huntsman School of Business has seen nearly a 300 percent increase in its Facebook fans. It now has more than 1,000 followers, and usually attracts 10 to 30 new followers per week.
"In addition to the Huntsman Facebook page, the Huntsman School has developed an actively growing Twitter page, YouTube page, and a LinkedIn group page; and we are excited to see the positive response we receive from users of each of these social-media outlets," said Mr. Morris.
Another electronic improvement for students this fall will be new interactive touch screens at the George S. Eccles Business Building that students can also use to connect to the new multimedia content and videos that have been created for them.
Students and faculty are encouraged to participate with a new virtual suggestion box found on the new student site to give input on ways to improve the Huntsman experience.
"While we really like what we have today," Ms. Gibbons said, "we need the collective input from more of our students to make this a truly student-directed site."


text:
Amy B. Quail Joins The Naples Trust Company
The Naples Trust Company announced today that Amy B. Quail has joined the firm as Vice President of Client Services.
Amy has 21 years of experience in the financial industry and most recently spent 15 years working with private wealth management clients at Neuberger Berman LLC and Goldman Sachs.
"Amy brings years of successful wealth management experience and we are fortunate to have her in our Tampa office," commented CEO Terry Igo.
She earned a B.S. degree in Finance at Boston College and has her Series 7, Series 63 & Series 66 licenses. She has been a Tampa resident since 2005 and volunteers with the American Cancer Society and Special Olympics.
This story is contributed by a member of the community and is neither endorsed nor affiliated with Naples Daily News.
Subscribe to the Naples Daily News
Need Help? Call us at 1-888-878-6842.
Monday-Friday: 6am-6pm / Saturday: 7am-3pm / Sunday: 7am-2pm


text:
State fines Ventura $603,000 over wastewater violations
The state is fining the city of Ventura $603,000 after its wastewater plant discharged water with excessive amounts of ammonia and other contaminants.
Of that, $303,000 will go toward the capital costs of a midtown environmental project, according to a tentative settlement reached between the city and the Los Angeles Regional Water Quality Control Board.
The violations at the plant, at 1400 Spinnaker Drive, took place between August 2010 and November 2012.
The City Council will vote on accepting the agreement at its Monday meeting.
Per its permit, the city may discharge 14 million gallons of treated wastewater daily into water polishing ponds that then go into the Santa Clara River estuary. When the permit was renewed in 2008, the city had to reduce its ammonia levels to 0.0045 milligrams per liter.
Ventura began a multimillion-dollar project to improve processes to lower the ammonia levels, during which the city received temporarily higher limits of ammonia discharge. But confusion over what that meant followed, and the city and state disagreed about how ammonia levels were calculated, City Manager Mark Watkins said.
"They said we were in violation. We didn't think we were," he said.
The fines are based on 194 violations found in data the city reports to the state, the settlement agreement says.
"Certainly, it's frustrating from a discharger's point of view. We're doing what we're being asked to do," Watkins said. "A couple years after the fact they go back and say, 'For that two-year period, you're out of compliance.' "
Ventura Water General Manager Shana Epstein said the city protested the violations, which resulted in the ability to invest more than half the penalties back into the city.
The city must pay the state $288,000, and an additional $12,000 will go toward administrative costs. The rest will go to the Katherine and Hartman Green Street Demonstration Project.
The project involves the installation of eight bioretention cells on Hartman Drive with drought-tolerant landscaping and more trees. The cells are designed to capture the initial water runoff that occurs during a storm or heavy rain. Such water is typically higher in pollutants.
The project had been put on hold because of a lack of funding.
"Whenever we have to pay violations, we prefer to have the money reinvested," Epstein said.
When the city sought a permit renewal for its wastewater facility late last year, the "calculations [were] clarified and everyone's in agreement," Epstein said.
The city received the permit, which goes through 2018.
Ammonia can threaten fish. "Even small amounts can hinder their gills' ability to transfer oxygen," according to a city staff report.
Also Monday, the council will discuss Ventura's 2014-20 capital improvement plan, which identifies and prioritizes infrastructure and road improvements, among other projects.
The discussion will include whether to redo the city's memorandum of understanding with the Ventura Unified School District on a pool proposed for the city's west side. Rather than taking the lead on the project, including design, construction and ongoing maintenance, the city wants to set aside roughly $1.4 million for the total cost.
Monday's council meeting will start at 7 p.m. at City Hall, 501 Poli St. It will follow Mayor Cheryl Heitmann's state of the city address, which will start at 6 p.m.
Subscribe to the Ventura County Star
Need Help? Call us at 1-877-710-6182.
Monday-Friday: 6am-3pm / Saturday: 6:30am-10:30am / Sunday: 7am-11am


text:
Join Now
Join ePHOTOzine, the friendliest photography community.
Upload photos, chat with photographers, win prizes and much more for free!
...I posted this as colour but the monochrome version was my own personal favourite. The pebbles seemed to me to be sliding under the mountains reflection.
|Canon EOS 5D MkIII
|Carl Zeiss Distagon T* 2/25mm ZE
|Recording media:
|RAW (digital)
|Monochrome Deep...
|10 May 2013 - 9:40 AM
|Black & white, Elgol, Highlands, Isle of skye, Landscape / travel, Lochaber, Scotland, Skye
|Voting Disabled
Dougie, super mono, I like that there is no clouds in your shot, allows the eyes to focus on the true quality of the reflection. Lovely image.........
Amazing shot! The water is so still, and makes such a great reflection! Such deep tones as well! Well done!
The colour was terrific, the mono is even more so. Fine detail in the f/g, exquisite reflection and a wide variety of tones; this time around my eye is drawn to the subtle lines of the slope rising from left to right and perfectly contained within the frame. A Cuillin peak that I could have climbed in my youth but did not know of until now . . .
I remember the colour well, but I do prefer this, simply for the harmony that it brings, the way it links the different levels that rise up through the frame.
I have been flicking back and forth between this B and W version and the original coloured one, Dougie, and whilst I can see the attractions of this one and appreciate the comments by yourself and others above, my own preference resides with the coloured: sorry to be out of kilter with the majority view.
But no matter, the composition and portrait format are so well suited, and the scene captured under wonderful conditions, sun and mirror flat water for the reflections and a glimpse of the loch bed.
It would be a dull world indeed if we all though the same way Ronnie.
I do like the vertical proportions Dougie. The 'real' bit only, at best, one third of the whole image. The depth to the reflection and fg detail occupying, quite rightly, most of the image. I almost feel the reflected mountain is like the roof at the opening of an under water cave or grotto - you could swim under it and disappear into the darkness beyond.
Excellent in mono Dougie, makes it seem even more stark!
It works equally well in mono for me, Dougie. Excellent.
I ADORE Scotland AND monochromes - so no surprises in that I really admire this Master's work!
Add a Comment
ePHOTOzine, the web's friendliest photography community.
Upload photos, chat with photographers, win prizes and much more.


text:
KYLE in NV
this is a great product that you must have with an oversized tank! otherwise you risk ripping off your fuel line.Read All Reviews
jeromy in NE
I liked the soft rubber of this one a lot better than the one that came with my accesories kit. The white reminded me to keep cleaning where the OEM black rarely got attention. It never came off and I never had an injector issue.Read All Reviews
Wes in ID
I used this spring with a J&D jetting kit & the combo worked awesome to cure the accel pump "studder" on the 2008 KTM 450 I worked on.Read All Reviews
Bradley in CA
Fit pretty good not perfect but good. Kind of raised the front part of the seat by a half inch which created a small gap between seat and radiator fenders. I wouldn't go any bigger than the 2.9, that will take you for many many miles of pure motoring pleasure.Read All Reviews
paul in NY
bought this for my 2015 ktm 450 sxf. looks great, don't get me wrong. but when i have a full tank in my bike and hit jumps or bumps i have gas leaking out all over me, which is super annoying. so now i just leave about half a tank in my bike when i ride and i don't get as much spillage.Read All Reviews
Benton in KS
One of the first things I bought for my bike. Kinda cheap insuranceRead All Reviews


text:
Advancement is a vital component to the Scouting program. Advancement recognizes Scouting's youth. To learn more ways that advancement can enhance your unit's program, contact Denney Jefferson, District Advancement Chairman, at firstname.lastname@example.com or (660) 909-4944
For Eagle project approval and boards of review, candidates MUST contact Denney Jefferson, Lone Bear District Eagle Scout Candidate Coordinator. He will work with our committee members who will be assigned to work with individuals.
Denney Jefferson
Lone Bear District Advancement Chairman
(660) 909-4944
Jim Houk
Lone Bear District Eagle Scout Candidate Coordinator
Eagle Scout Rank Application
Eagle Scout Service Project Workbook
Alternate Eagle Scout rank merit badges


text:
The human population has been thinned out by terrible diseases countless times in history. Millions of people have been wiped out by various diseases in the past several hundred years. Throughout our history, people have been ravaged by diseases that were brought on by a number of different factors. Sometimes the source of the disease was an animal or an insect. At other times, just a single human being. Whatever the cause, the 10 diseases on our list below have caused millions of deaths throughout human history.
1. Black Death
The Black Death is thought to have caused as many as 75 million deaths in the middle ages. It is thought that this dreaded disease started in Central Asia and was brought to Europe in the 1340s. About 25 million people died in Europe, and it is believed that the disease killed as much as 2/3 of the population of Europe. It is now believed that the Black Death was caused by a type of flea that is carried by rodents. Lack of proper sanitation is probably the major cause of the spread of the Black Death, or the Black Plague.
2. Polio
Poliomyelitis (polio) is a viral disease of an acute nature that spreads between human beings. It seems to spread by the fecal/oral route primarily. About 90% of polio infections do not result in any symptoms. The problems occur if the virus gets into your blood stream, which then attacks the central nervous system in a small minority of cases. If it does, it will infect and damage motor neurons, which leads to weakness of muscles and paralysis in some cases. About 10,000 deaths have resulted from polio, but hundreds of thousands were paralyzed, including President Franklin Roosevelt, before a vaccine was discovered.
3. Smallpox
Smallpox has ravaged human populations many times in history. It is thought that smallpox reduced Native American populations from 12 million to 235,000 in the 17th century. Smallpox is brought on by two viruses: Variola major and minor. The deadlier form is Variola Major and it causes about 35% of those infected to die. Even if you do not die from smallpox, you will be scarred for life. Also, some people go blind due to ulcerations of their corneas. Smallpox is thought to have killed 60 million Europeans in the 18th century. Fortunately, smallpox is one disease that has been completely eradicated throughout the world.
4. Cholera
Cholera is a diarrheal disease that is brought on by the Vibrio cholerae bacterium. It is usually transmitted to people by the ingestion of water or food that has bee contaminated. Cholera is a very deadly disease, and a person can actually die within a few hours if there is no treatment. Usually, the disease will start with diarrhea, to shock, and then death in a few days if no treatment is given. About 12,000 people have died from this disease in the last 20 years.
5. Ebola
This virus first began in 1976 when there were outbreaks in Zaire and Sudan. It is thought to be a zoonotic virus that is causing problems today with the gorilla population in Central Africa. No one is sure what the exact source of the virus is, but there are theories that the fruit bat is responsible. Someone who is suffering from the Ebola virus can have fever, vomiting, diarrhea, pain and bleeding. Mortality is up to 90% of those infected. About 160,000 have died in the last decade from Ebola.
6. Malaria
Malaria is one of those diseases that is still ravaging the world. Believe it or not, more than 2.7 million people die from malaria every year. This is a disease that is carried by mosquitoes and is caused by a protozoan parasite. It is very common in tropical and subtropical parts of Africa, Asia and the Americas. It infects about 500 million people each year and kills several million per year. Malaria is one of the most serious public health problems in the world. No vaccine is available for this disease, but there are some drugs that you can take constantly to reduce your risk.
7. Spanish Flu
This was what caused the 1918 flu pandemic, and it was a category 5 influenza pandemic. Many victims were healthy young people, rather than the old and young, as is typical with flu outbreaks. This pandemic lasted from 1918-19, and spread even as far as the Arttic and to remote islands in the Pacific. It is believed that more than 50 million died, which might have made it more deadly than the Black Death. This very high death count was due to the high rate of infection of as high as 50%.
8. Influenza
The common flu is a disease of mammals and birds that is brought on by RNA viruses that belong to the family orthomyxoviridae. While many cases of influenza are not deadly, in serious cases, it can cause pneumonia, which can be very serious in young and old people. Flu is unrelated to the common cold and is a much more serious disease. The common flu causes 36,000 deaths each year.
AIDS is an assortment of infections and symptoms that happen because of damage to the immune system caused by HIV. The later stages of this disease leave the victim very vulnerable to infections and various tumors. It is thought that HIV started in Africa in the 20th century. About 40 million people around the world currently have HIV, if not full blown AIDS. Fortunately, drugs have been developed that can at least help to ward off HIV from turning into the full AIDS disease. Still, no vaccine has been found yet to fully cure this disease.
10. Tuberculosis
One does not hear as much about tuberculosis, but it is still a killer. More than 3 million per year still die from TB around the world. Luckily many of the people infected never have any symptoms, but about 10% do eventually develop TB. Over a few months or years, TB slowly destroys your lungs, and eventually you can spit up blood. Fortunately, like the Black Death, TB is treatable with antibiotics. It still can take a few months to clear up this nasty disease with proper treatment, however.


text:
Archive for the 'Roadster Racing Association of Oregon' tag
Four-Links – Japanese concept cars, MGBGTV12, Autoettes, Oregon land-speed racing
* From Pink Tentacle, a gallery of Japanese concept cars and show cars, most of which you've probably never seen before. (via)
* If your MGB GT's floor is all rusted out anyway, why not completely reengineer the whole thing to accept a Jaguar V-12? (via)
* I've yet to find any niche of the collector car hobby that doesn't have at least one person dedicated to it. The Autoette Project blog just proves my point.
* Who knew there was a Roadster Racing Association of Oregon? Thanks to Flat-Out Press, not only can you read a brief intro to the organization, you can also purchase a reproduction RRAO timing tag.
* Finally, a flying Beetle.


text:
This photo is awaiting approval and will be posted soon.
Play our fun game and find out if the one you like likes you back. Confide in us if you think you'd hit it off by clicking: Yes, No, or Maybe. We'll anonymously find out and let you know if the feeling is mutual. You have nothing to lose!
You've already said YES! If the feeling is mutual, we'll let you both know.
You've already said No. If you've changed your mind, let us know. If you say Yes, we'll anonymously find out if the feeling is mutual. You have nothing to lose!
You've already said Maybe. If you've changed your mind, let us know. If you say Yes, we'll anonymously find out if the feeling is mutual. You have nothing to lose!
You both said YES! The feeling is mutual. Now the rest is up to you! Say Hi and get the conversation started.
I enjoy Foreign and Indy films, art museums, cooking together, Bill Maher, VT's Bernie Sanders, Hillary Clinton, reading the Sunday NY Times: the wonderful magazine and Book review, etc..I don't require anything extreme, just interested in meeting an intelligent, kind and caring man. I have been to Paris, enjoyed The Louvre, The Musee' D'Orsay, The L'Orangerie and The Museum of D'Art Moderne etc. I enjoyed Rome and Florence also as I just love art! I picked up some fun CDs in Rome that are jazzed up Classical Music done by a Group called Rondo Venitziano. So now it's time to keep enjoying! So what interests you? Two can have a lot more fun than one!
Copyright © 2015 Spark Networks® USA, LLC. All rights reserved.Spark Networks USA, LLC is a wholly-owned subsidiary of Spark Networks, Inc., a NYSE MKT Company (LOV)
Spark Networks USA, LLC does not conduct background checks on the members or subscribers of this website. However, the safety and security of our members is our top priority. We urge all members to follow our online safety tips.
The Color Code icon tells you that this member has taken the FREE Color Code Personality Test and wants to share his/her results with you. You can read all about their Color Code profile on the new Color Code tab.
The Color Code, by Dr. Taylor Hartman, is one of the most insightful personality tests in existence, and is made up of four personality Colors, or driving Core Motives. The Color Code teaches you the real motives behind your actions and how to better relate to other personality types.
Don't miss this chance to get valuable, life-changing personal insight, it only takes less than 15 minutes and it's FREE!
Want to read more about this member's color code?
Read more now
Any woman who has more than one child can tell you how different each child is from birth. You are born with your personality intact. The Color Code is based on your natural, innate personality type. Of course, people may change over time, but your Core Color will always remain the same.
Sometimes it is difficult to choose from the four options given, but there is usually one that fits better than the rest, or at least one that you could see yourself as more so than the others. If you're still unsure, try asking someone who knows you well, such as a parent or sibling. They can give clarity on areas of your personality that you may not notice.


text:
MP for Hornsey and Wood Green
Queen Mum stuff! That's what I call it when I am invited to Lib Dem local party social events or meetings to gee up the troops. Troop geeing up is variable – dependent on nature of local party. This was for Camden Liberal Democrats and held in Belsize Ward. Hosted by Alexis and Laura – who really pulled out all the stops for fantastic, proper, real cooked food! I am there to talk to people and enthuse them for giving their all – be that money, time or blood. And if the food is good – the giving is greater.
I work my way around the attendees and also make a speech. Of course, the Hornsey & Wood Green story (or how I overturned a Labour lead over me in '97 of 26,000 into a 2,400 majority in 2005) is stirring stories for girls and boys in Labour seats. I do my stuff – and if I were a betting man I would put some money on Lib Dems gaining quite a few council seats next May. And in the General – well watch out Glenda!
Published and promoted by and on behalf of Liberal Democrats, 62 High Street, Hornsey, N8 7NX.
Site produced by Puffbox in association with Harrisment.
This work is licenced under a Creative Commons Licence.


text:
So, I have a new web log up (finally). I'm not going to link to it here, but if I know you, feel free to contact me privately, and I'll give you the link. I will no longer post any new entries to this site (but I do plan to leave it up for historical purposes).
added August 9, 2014: I guess Drupal updates the monthly archive on its own periodically, so the post indeed showed up in the monthly archive eventually. Now, I've re-dated it (a significant portion of a year earlier), because I was mixed up about which of our trips together to San Francisco it talked about.
--original content is below--
I noticed tonight that I had an unpublished entry from 2010 where I talked about our trip to San Francisco that year. It probably wasn't done yet (thus why it wasn't published), but I can't finish it now, and I wanted to make it visible. I haven't figured out yet how to make it show up in the archive list yet, but here's a link to it.
*sigh* I've sensed a potential breakthrough (and been wrong about it) enough times, that I can't be sure any more. I've come to the point where I've mostly stopped making predictions about how I'm going to feel and which things I'm going to finish when. However, my optimistic side is very hopeful, and the fact that it's peeking out is good news in and of itself.
For anyone who knows me well, it will probably come as no surprise that I was quite relieved when I came up with a reason why this whole situation is (mostly) my fault. For those of you who don't know me well and, yet, are still interested, I hope by the time you finish reading this "book", you'll have a general idea.
Well, I took a look at the online account stuff, and I can see that the US Treasury has deposited the check that I sent to pay my federal taxes. That confirms a few different relief-inducing things:
So, this evening (actually, I guess yesterday evening now) I had a rather new experience in my recovery. I actually felt fairly positive and optimistic close to the end of the work day. This is a completely new thing for me!
Earlier in the day (around lunch), I felt my normal daytime mood slump. There was a specific reason why my mood was down (one which I may decide to share at some point, depending on how the situation ends up).
Well, it finally happened. It's about time, and as I strongly suspected it would be, it was music that triggered it.
Half a week later... and if anything, the extremes of my feelings are worse instead of better. If given the chance, I'm not sure whether I'd throttle her or thank her. There's not much room for anything in between right now. Either way, I'm pretty sure I'd be bawling while doing it.
I know she wasn't happy, though. I honestly hope she finds happiness. That's the honest truth.
Now that I have some time, I figure I should let everyone know that I was rear-ended this morning. Me and the other driver were both unhurt. No one else was in our cars, and our two cars were the only ones involved. Honestly, it was very minor. What the other driver gave as his description matched mine.
You know, I was originally writing one of my "extended novel" form posts., but I think I'm going to use this lockup as a signal that I should be doing something a lot shorter. What I was really trying to say was that as strange as it seems, I've decided to look at a small slip that resulted in something taking a lot longer than it should have as a sign that I'm gradually getting back to much closer to normal.


text:
Researchers at the National Cancer Institute (NCI), part of the
National Institutes of Health (NIH), have found that inhibition
of the same protein produces different effects in mouse cell lines
depending on whether those cell lines express normal or cancerous
forms of Kit, a cell surface receptor critical for the development
of some kinds of blood cells. These findings, appearing in the journal
Blood online *, November 2004,
reveal a potential new target for treating certain blood cell disorders.
A specific mutation affecting the catalytic domain of the Kit receptor
results in a cancerous form of Kit found in patients with mast cell
disease and some forms of acute myeloid leukemia. This particular
Kit mutant, known as D814Y, is resistant to Gleevec, a drug
used to treat a variety of diseases associated with Kit and related
proteins. Other types of cancer, including gastrointestinal stromal
cell tumors, have different Kit mutations that are sensitive to
Gleevec. One potential way to circumvent the Gleevec-resistant form
of Kit is to target one or more of the proteins that are activated
by Kit.
NCI researchers Diana Linnekin, Ph.D., and Tanya Jelacic, Ph.D.,
found that inhibition of one such Kit-activated protein, PKCδ (PKCdelta)
(a member of a family of protein kinases involved in cell signaling),
reduced the growth of a mouse mast cell line expressing the D814Y
mutant Kit by approximately 40 percent. In contrast, PKCδ (PKCdelta)
inhibition did not suppress the growth of normal mast cells. "This
is the first demonstration of a function change in PKCδ (PKCdelta)
resulting from a cancerous mutation in a growth factor receptor," said
Because anti-PKCδ (PKCdelta) drugs would specifically
inhibit the growth of mutated cells and not affect normal ones,
these results suggest
that PKCδ (PKCdelta) may be a therapeutic target for
mast cell disease associated with the D814Y mutation in Kit and
possibly for other disorders
associated with Kit catalytic domain mutations. "This work
is a promising study on cancer inhibition," said Linnekin.
"Dr. Jelacic and I believe that follow-up work with human
cell lines, as well as work in mouse models of cancer, would be
For more information about cancer, visit the NCI Web site at
http://www.cancer.gov or call
NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).


text:
One particular two-story house in the 200 block of NW 17 has two sets of porch steps.
They call it "The Twin House."
Who calls it that? The last three families to live there.
One particular two-story house in the 200 block of NW 17 has two sets of porch steps.
They call it "The Twin House."
Who calls it that? The last three families to live there.
These families either moved into the house with twins, found out they were expecting twins while living there, or found out and had twins born while living at 209 NW 17.
All three sets were boy/girl twins.
Chelsea Smith and husband, Brady, were about to take the bar exam in the summer of 2011.
To relax a little, they decided to attend a neighborhood cocktail party given for people who moved in that year.
A woman Chelsea had never met, Jennifer Gaines, walked up to her and Brady.
Jennifer and husband, Patrick, were the first of the three couples.
"The first thing I said to them was 'Make sure your birth control is good, if you are not ready to have kids, because the last two (couples) in that house had boy/girl twins,'" Gaines said.
"Chelsea and her husband were taken aback, laughed a little, and probably ran away from us as fast as they could."
Chelsea said she walked away thinking, "That was weird." But Jennifer told people the Smiths lived in their old house. So others started coming up saying, "Oh, the twin house."
"I thought it was crazy," Chelsea said. "I thought, 'Well a house doesn't make you have twins.'
"I was like, 'Have you heard that house had twins in it?' and Brady was like, 'No.'
And, I said 'How strange.'"
They brushed it off and went on.
Chelsea first thought she might be pregnant on New Year's Day 2012.
She had an ultrasound done a short while later.
The person giving the ultrasound said, "Oh Chelsea you're going to freak out."
Chelsea told her she was prepared, no big deal.
Then the woman said, "No, there's two."
She wasn't prepared.
"I don't really think I could even verbalize it for probably 24 hours," Chelsea said.
"I didn't even say anything when she said there were two. We're like, 'You've got to be kidding me.'"
Then, the comments at the cocktail party came to mind.
"Immediately," said Brady, who was with Chelsea for the ultrasound.
On Aug. 16, Chelsea gave birth to girl/boy twins, Vivian Elaine Smith and Elliot Lowry Smith.
Not long after finding out that twins were on the way, the Smiths saw some neighbors at an event. Chelsea mentioned it, and the neighbor said, "I'm texting Jennifer right now."
Not a surprise
Patrick and Jennifer Gaines were married in June 2000 and moved into the house in April 2002. The twins, daughter Cooper Christian Gaines and son Patrick Byrne Gaines Jr., were 4 months old when the Gaineses moved into the house.
Continue reading this story on the...


text:
- Tuesday, April 02, 2013
Advance Viewing and Reception for Exhibition Funders and Director's Circle Members
Part of Christian Marclay: The Clock
Date + TimeTuesday, April 02, 2013
7:00 p.m. - 9:00 p.m.
LocationFourth-floor gallery
Director's Circle members are invited to meet artist Christian Marclay and be among the first to see The Clock at SFMOMA during this exclusive screening and reception.
Please note: Seated capacity is limited to only 81 visitors at a time. Admission to the installation is on a first-come, first-served basis, with no time limits for viewers; queues may be expected.
Admission + Ticketing
For more information, or to join Director's Circle, please contact Jacqueline Rais at 415.357.4085 or firstname.lastname@example.com.
Not a member? Join today!


text:
- Home
- News
- Sports
- Opinion
- Obituaries
- Features
- Special Sections
- Classifieds
- Public Notices
Forgot Password? | Not a User? Sign up
Elizabethtown has received an unexpected gift from the state.
Executive Assistant Charlie Bryant this week announced State Rep. Jimmie Lee, D-Elizabethtown, has secured $230,000 to make improvements to Pine Valley Drive.
The money was located by Lee after he and the city identified the street as ripe for several key improvements.
If you currently subscribe or have subscribed in the past to the The News Enterprise, then simply find your account number on your mailing label and enter it below.
Click the question mark below to see where your account ID appears on your mailing label.
|ZIP Code:


text:
Watch the Denver Broncos Online
Find out what will be done at the quarterback position when you watch the Denver Broncos online during this season.
Watch the Denver Broncos Online.
What to do with the quarterback?
John Elway, executive vice president of football operations, and head Coach John Fox have to find out if Tim Tebow is the future for this team, and that means playing him throughout this season. The Broncos need to trade Kyle Orton, if not now, then when a starter around the league goes down with an injury before the trading deadline in October. There is a great deal of money involved in this scenario, but not as much if they don't know what they have in Tebow well before the next draft. They are definitely going t test him in training camp and as well as in preseason.
Converting defenses is always tough and can take a few years to be successfully completed. The attempt to go with a 4-3 will be interesting to see who will fill the opening-day middle linebacker slot. What about the defensive tackles? Can they be one-gap penetrators? Will Elvis Dumervil hold up on run downs with his hand on the ground. And how about Orlando Franklin? Can this second-round rookie develop quickly? Perhaps the Broncos need to seek the services of a proven veteran.
You won't need any proven record when you jump on the chance to see live streaming video coming over the Internet onto your own computer when you watch the Denver Broncos online.


text:
This Site:
Defining Moments
Picture Collections
Themed Collections
Historical Maps
Site Search
Dobbins Mills Dakota Territory
Hot Springs
Indians Getting Beef
The Deadwood Reduction Works
Cattle Roundup
Calamity Peak. Near Custer, named after "Calamity Jane,"
Indian in War Bonnet
Round-up at Moss Agate
The Deadwood Stage
Branding Calves on Roundup
Log Home
Phantom Ridge
General Miles and staff
US Army Artillery
Hostile Sioux Indian Camp
Railroad Surveyor Camp
Freighting in the Black Hills
Soldiers with Lacota Sioux Indian Scouts
Devils Tower
Cowboys Eating Dinner on a Cattle Drive
Deadwood in 1888
Deadwood Grand Lodge
Spearfish Falls
Antelope Hunt
Sunday Gulch
Deadwood, South Dakota
Oglala Indian Chief
Deadwood Gold Smelter
Parade in Deadwood
Bill Cody
Deadwood, Dakota Territory
Chicago Parade
Viewing Hostile Indian Camp
Band of Indians
Men of the Old West
Bath House
Big Foot's village on reservation
Rounding Up Mustangs
Renegade Indian
Surveyors Camp Site
Site Copyright 2006-2014
www.old-picture.com. Contact email@example.com


text:
Article Index
- Surging Corn Prices Making Hay for Commodities Producers
- Buy, Sell or Hold: A Rebound is Sprouting for Monsanto Co. (NYSE: MON)
- How to Profit From the Russian Wheat Shortage
- BHP Billiton's Bid for Potash Could Spark Surge of M&A Activity in Agribusiness Sector
- Drought Forces Russia to Ban Grain Exports
- Buy, Sell or Hold: Deere and Co. Thrives on Strong Global Trends and Flawless Execution
- Can Corn Prices Make a Comeback?
- Brazil Wins Eight-Year Battle Against U.S. Cotton Subsidies After Threatening Sanctions
- Terra Industries Favors Competing Offer in Raging "Fertilizer Wars"
- How to Profit From the "Fertilizer Wars"
- Two Ways to Profit From Wall Street's "Soft Commodity" – Cotton
- Exxon Mobil and Shell Post Record Income but Demand and Production Weigh on Shares
- Archer Daniels Midland Oilseed Harvest Reaps Big Rewards
Buy, Sell or Hold: A Rebound is Sprouting for Monsanto Co. (NYSE: MON)
Indeed, the drop in the dollar's value has investors and speculators seeking physical commodities to park their funds in. This has caused the prices to expand in the grains sector, and when next year rolls around, you can expect that seed manufacturers will have priced next year's crop accordingly. So while the trading pits and the farmers are all banking money now, the next round of inflation is already being calculated into next year's margins.
And we can use those inflationary expectations to grow some profits of our own by investing in Monsanto Co. (NYSE: MON) - one of the world's largest seed producers.
Think of it as a "picks-and-shovels" play to capitalize on all of the farmers rushing to cash in on surging commodities prices.
How to Profit From the Russian Wheat Shortage
Having grown up on a working farm in Oregon, I understand this all too well. Those days taught me a lot about hard work and patience. Four decades later, as I read news stories about the current travails of Russian wheat farmers, the memories of getting up on wet winter mornings for the pre-dawn goat milking - or having to drive a tractor when I was only six years old - engender a lot of empathy for the difficult challenges the wheat farmers face.
Wild fires are racing through unharvested wheat fields, the result of a Russian heat wave that has destroyed more than one-fifth of that country's wheat crop. In addition to causing the farmers considerable pain, the crop losses have caused wheat prices to double this summer.
This has spawned an export ban in Russia, which effectively removes the third-largest exporter in the world from the market. It's also created a major profit opportunity for U.S. investors.
Let me explain.
For strategies that will help you profit from the Russian wheat shortage, please read on....
BHP Billiton's Bid for Potash Could Spark Surge of M&A Activity in Agribusiness Sector
Canada-based Potash, the world's largest producer of potash, yesterday (Tuesday) rejected an unsolicited takeover bid from the Australia mining giant, calling the offer "grossly inadequate."
The fertilizer company also quickly adopted a so-called poison-pill defense to fend off would-be suitors, though it said it would be open to a transaction if the price were right.
Drought Forces Russia to Ban Grain Exports
Wheat rose to a 23-month high after Russia, the world's third-largest grower, announced a ban beginning Aug.15 that will last through the end of the year. Corn and rice prices also surged yesterday after Russian Prime Minister Vladimir Putin said a ban on those grains would be "appropriate" in light of skyrocketing prices.
Domestic grain prices gained 19% last week, faster than at the peak of the global food crisis in 2008. The ban includes wheat, barley, rye, corn and flour exports, according to the government decree that also set aside nearly $1.2 billion for stricken farmers.
Buy, Sell or Hold: Deere and Co. Thrives on Strong Global Trends and Flawless Execution
In typical fashion, Deere continues to be conservative in guidance. And as I will explain below, the agricultural cycle this year is poised for a large upside surprise, as it is at the very beginning of a prolonged secular pickup.
The bottom line of Deere's performance last quarter is a prelude of things to come. Agriculture is zooming, and thus machinery in that sector is - and will continue - to command premium pricing. At the same time, global inflation is picking up slightly, but is still very subdued, which will help margins some more.
Can Corn Prices Make a Comeback?
Still, there's reason to believe that corn prices will rebound.
The summer season could be particularly harsh following a better-than-average spring, and rumors that China is gearing up to make a huge purchase so far has helped keep corn prices afloat - and could even send them higher. But before that happens there are some substantial headwinds for the crop to overcome.
Brazil Wins Eight-Year Battle Against U.S. Cotton Subsidies After Threatening Sanctions
Start the conversation
Leave a Reply
Terra Industries Favors Competing Offer in Raging "Fertilizer Wars"
Start the conversation
Leave a Reply
Yara made a $4.1 billion bid for Terra in February, in an all-cash deal valued at $41.10 per share. Per their agreement, Terra can give Yara notice it intends to break the contract, giving Yara five days to provide a better offer. If the break-up goes through, Yara gets a cozy fee of $123 million.
CF came forward March 2 with a $4.75 billion bid -- $37.15 in cash and 0.0953 per share for each Terra share.
How to Profit From the "Fertilizer Wars"
There's nothing like scarcity and supply disruptions to fuel violent price spikes. And there's nothing like the basic human needs for food and water to light that fuse.
Today's world food supplies run on razor-thin inventories.
While the food riots of 2008 have all but disappeared from our short-term memories, the threat of them returning grows stronger with every passing day.
According to the World Bank, food prices increased 83% between February 2005 and February 2008. In April 2008, when the United Nation's World Food Programme warned that a "silent tsunami" of hunger was sweeping the globe because of soaring food prices, it was more than just a clever sound bite tossed off by a bureaucrat: It was a warning that the world's poor were being squeezed as increasingly higher portions of their family incomes were being spent on the food they required for their very survival.
Improved fertilizers will be a key to the solution of this problem. And they won't just promote crop growth - savvy investors who fertilize their portfolios will be pleased with their profit harvest.
Let me explain ...
To discover how to profit from zooming fertilizer prices, please read on....
Two Ways to Profit From Wall Street's "Soft Commodity" – Cotton
Take such traditional "breakfast club" commodities as sugar, cocoa, coffee and orange juice. They all enjoyed a great year, despite bearish forecasts of doom and gloom. Sugar and cocoa even traded at multi-decade highs.
Similarly, cotton got a bad rap going into 2009, though it motored into the end of the year with a tidy profit, rising on the standard laws of supply and demand.


text:
This might be the sexiest we've ever seen Demi Lovato look!
The singer just debuted her latest music video for "Neon Lights" -- and she's showing off her sexy silhouette and dance moves!
Check out the video above to see Demi's "Neon Lights" video.
The 21-year-old definitely makes partying in the rain look like a lot of fun, and we've never seen the former Disney star show off such sensual moves before -- it's probably one of Lovato's most mature videos to date.
What do you think of Lovato's scantily-clad scenes? Tell toofab in the comment section below and check out the gallery to see even more child stars then and now!
© 2015 EHM Productions, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.
In partnership with TMZ.com | Privacy Policy | AdChoices